CMT-MCM3AP

MCM3AP | 2017

What Is CMT-MCM3AP?

CMT-MCM3AP is a type of CMT caused by autosomal recessive mutations in the MCM3AP gene. This gene provides instructions for making GANP, a protein required for exporting messenger RNA from the cell nucleus, a process essential for normal cell function, including in peripheral nerves. Mutations in the MCM3AP gene disrupt this export process, leading to impaired nerve signal transmission.

CMT-MCM3AP is autosomal recessive, meaning that both copies of the gene must have a mutation to cause this subtype.

Clinical Features

The age of symptom onset in CMT-MCM3AP is variable, ranging from childhood to adulthood. Symptoms typically begin in the lower extremities and progress over time to involve the upper limbs. Nerve conduction studies usually show somewhat slowed conduction velocities and reduced amplitudes, consistent with an axonal form of CMT.

CMT-MCM3AP symptoms may include:

  • Weakness in the feet and lower legs
  • Muscle atrophy
  • Foot drop
  • Reduced or absent reflexes
  • Reduced sensation
  • A steppage-style walking pattern
  • Foot deformities, including high arches, and hammertoes (clawed toes)
  • Progressive involvement of the hands and forearms
  • Difficulty with fine motor skills and manual dexterity
  • Additional symptoms not listed here

Disease Course

CMT-MCM3AP shows wide variability in severity and progression. Some individuals are mildly affected, while others develop a more severe disease. Disease progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
CMT-MCM3AP

Classification
Unclassified Subtypes

Neuropathy Type
Axonal

Inheritance Pattern
autosomal recessive

Genetic Context

HGNC-Approved Gene Symbol
MCM3AP

Gene Full Name
Minichromosome Maintenance Complex Component 3 Associated Protein

Chromosome
21q22.3

Zygosity of Responsible Variant
Homozygous or Compound Heterozygous

Variant Mechanism
Loss of Function (LoF)

ClinVar Pathogenic Variants

View CMT-MCM3AP ClinVar Variants

CMT-MCM3AP OMIM Entry

CMT-MCM3AP OMIM

MCM3AP OMIM Entry

MCM3AP OMIM

More Info

CMT-MCM3AP Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

MCM3AP in Recessive Charcot-Marie-Tooth Neuropathy and Mild Intellectual Disability

Authors

Ylikallio, E., Woldegebriel, R., Tumiati, M., Isohanni, P., Ryan, M. M., Stark, Z., Walsh, M., Sawyer, S. L., Bell, K. M., Oshlack, A., Lockhart, P. J., Shcherbii, M., Estrada-Cuzcano, A., Atkinson, D., Hartley, T., Tetreault, M., Cuppen, I., van der Pol, W. L., Candayan, A., Battaloglu, E., … Tyynismaa, H.

Publication Date
June 19, 2017

Updated: July 18, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


Close-up of a doctor’s hand holding a prescription pad while a patient’s wrist is wrapped with metal chains.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Illustrated graphic showing large ‘404’ numerals with people interacting with data screens and servers, alongside text reading ‘CMT Genetic Testing Error 404: Gene Not Found’ and ‘Examining Why Less Than Half of All Who Have Charcot-Marie-Tooth Disease Are Not Able to Obtain Genetic Confirmation of Their Disease.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.


Illustrated cover graphic showing a split landform with branching directional arrows, two people with question marks above their heads, and the title ‘SORD Deficiency: Decoding This Newly Discovered and Confusing CMT Subtype.


CMT-SORD: What Is This Unique CMT Subtype?

CMT-SORD is a newly discovered CMT subtype driven by toxic sorbitol accumulation. This article explains how "SORD" works, why this subtype is different, and how it led to the fastest-moving therapeutic program in CMT history.